TY - JOUR
T1 - Tumours of the brain and presence of antibodies to Toxoplasma gondii
AU - Ryan, Philip
AU - Hurley, Susan F.
AU - Johnson, Alan M.
AU - Salzberg, Michael
AU - Lee, Marjorie W.
AU - North, J. Brian
AU - Mcneil, John J.
AU - Mcmichael, Anthony J.
PY - 1993/6/1
Y1 - 1993/6/1
N2 - The possible association between prior infection with the protozoan Toxoplasma gondii and development of brain tumours was investigated as part of two Australian population-based case-control studies of adult brain tumours. One study, based in Adelaide, South Australia, collected blood from 73 subjects with glioma, 53 subjects with meningioma and 348 controls. The other study, based in Melbourne, Victoria, collected blood from 44 subjects with glioma and 67 controls. All tumours had been verified histologically. IgG antibodies to T. gondii ware measured using Enzyme Unked Immunosorbent Assay (ELISA) techniques. In both the centre-specific and combined analyses, there was no difference between subjects with glioma and controls in the prevalence of antibody test-positivity (35% test-positive in glioma versus 33% in controls, age-, sex- and centre-adjusted odds ratio (OR)=1.00, 95% confidence interval (Cl): 0.64-1.56). In the Adelaide study, there was a statistically significant increased risk of meningioma associated with antibody test-positivity (47% test-positive in meningloma versus 31% in controls, P=0.02, adjusted OR=2.09, 95% Cl: 1.14-3.83). Our results do not support the hypothesis that antibody positivity to T. gondii is a risk factor for glioma, but suggest that it might be associated with meningioma.
AB - The possible association between prior infection with the protozoan Toxoplasma gondii and development of brain tumours was investigated as part of two Australian population-based case-control studies of adult brain tumours. One study, based in Adelaide, South Australia, collected blood from 73 subjects with glioma, 53 subjects with meningioma and 348 controls. The other study, based in Melbourne, Victoria, collected blood from 44 subjects with glioma and 67 controls. All tumours had been verified histologically. IgG antibodies to T. gondii ware measured using Enzyme Unked Immunosorbent Assay (ELISA) techniques. In both the centre-specific and combined analyses, there was no difference between subjects with glioma and controls in the prevalence of antibody test-positivity (35% test-positive in glioma versus 33% in controls, age-, sex- and centre-adjusted odds ratio (OR)=1.00, 95% confidence interval (Cl): 0.64-1.56). In the Adelaide study, there was a statistically significant increased risk of meningioma associated with antibody test-positivity (47% test-positive in meningloma versus 31% in controls, P=0.02, adjusted OR=2.09, 95% Cl: 1.14-3.83). Our results do not support the hypothesis that antibody positivity to T. gondii is a risk factor for glioma, but suggest that it might be associated with meningioma.
UR - http://www.scopus.com/inward/record.url?scp=0027305314&partnerID=8YFLogxK
U2 - 10.1093/ije/22.3.412
DO - 10.1093/ije/22.3.412
M3 - Article
C2 - 8359956
AN - SCOPUS:0027305314
SN - 0300-5771
VL - 22
SP - 412
EP - 419
JO - International Journal of Epidemiology
JF - International Journal of Epidemiology
IS - 3
ER -